Aravax Presents Additional Positive PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019 Annual Meeting Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma MELBOURNE, Australia, June 04, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage...

Aravax to Present Additional PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019 Annual Meeting Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy MELBOURNE, Australia, May 28, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage biotechnology company focused...

Aravax Presents Positive PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting Data show that PVX108, a peptide-based immunotherapy, has a highly favorable safety profile for the treatment of peanut allergy MELBOURNE, Australia, Feb. 24, 2019 (GLOBE NEWSWIRE) -- Aravax, a...

Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting Study designed to evaluate safety and tolerability of a novel peptide-based immunotherapy to treat peanut allergies MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage...